Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine

International Journal of Clinical Practice, Supplement

Volumn , Issue 105, 1999, Pages 25-33

  Dowson, Andrew J ^a   Ashford, Elizabeth A ^b   Prendergast, Susan ^b   Hassani, Habib ^b   Roberts, Gerard W ^c   Flöter, Thomas ^d   Szczudlik, Andrzej ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Frankfurt Pain Center ^*

^d Frankfurt Pain Center   (Germany)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acute migraine; Dosing preferences; Efficacy; Oral sumatriptan; Tolerability

Indexed keywords

SUMATRIPTAN; SEROTONIN AGONIST; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PHOTOPHOBIA; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; ACUTE DISEASE; ADOLESCENT; AGED; ANALGESIA; MIDDLE AGED; MULTICENTER STUDY; PATIENT PARTICIPATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALGESIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT PARTICIPATION; PATIENT SATISFACTION; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 33749214772     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral-defining study. Eur Neural 1991; 31: 300-305.
2. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306-313.
3. Cutler N, Mushet GR, Davis R et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45(Suppl 7): S5-S9.
4. Sargent J, Kirchner JR, David R et al. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multi-center study. Neurology 1995; 45(Suppl 7): S10-S14.
5. Nappi G, Sicuteri F, Byrne M et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neural 1994; 241: 138-144.
6. Ferrari MD, James MH, Bates D et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330-338.
7. Goadsby PJ, Zagami AS, Donnan GA et al. Oral sumatriptan in acute migraine. Lancet 1991; 338: 782-783.
8. Pfaffenrath V, Cunin G, Sjonell G et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-190.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8: 1-96.
10. Salonen R, Ashford E, Gibbs M et al. A double-blind, randomized, crossover study to assess patient preference and the efficacy and safety of oral sumatriptan 25 mg, 50 mg, 100 mg in the acute treatment of migraine. J Fam Pract 1998; (Suppl): M11